584 related articles for article (PubMed ID: 17850661)
21. Genome-Wide Transcriptome Analysis of Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Positive Breast Cancers by Ribonucleic Acid Sequencing.
Chen P; Song W; Liu L
Gynecol Obstet Invest; 2018; 83(4):338-348. PubMed ID: 29241203
[TBL] [Abstract][Full Text] [Related]
22. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
23. Classifying the estrogen receptor status of breast cancers by expression profiles reveals a poor prognosis subpopulation exhibiting high expression of the ERBB2 receptor.
Kun Y; How LC; Hoon TP; Bajic VB; Lam TS; Aggarwal A; Sze HG; Bok WS; Yin WC; Tan P
Hum Mol Genet; 2003 Dec; 12(24):3245-58. PubMed ID: 14570715
[TBL] [Abstract][Full Text] [Related]
24. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
25. Impact of DNA amplification on gene expression patterns in breast cancer.
Hyman E; Kauraniemi P; Hautaniemi S; Wolf M; Mousses S; Rozenblum E; Ringnér M; Sauter G; Monni O; Elkahloun A; Kallioniemi OP; Kallioniemi A
Cancer Res; 2002 Nov; 62(21):6240-5. PubMed ID: 12414653
[TBL] [Abstract][Full Text] [Related]
26. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes.
Loo LW; Grove DI; Williams EM; Neal CL; Cousens LA; Schubert EL; Holcomb IN; Massa HF; Glogovac J; Li CI; Malone KE; Daling JR; Delrow JJ; Trask BJ; Hsu L; Porter PL
Cancer Res; 2004 Dec; 64(23):8541-9. PubMed ID: 15574760
[TBL] [Abstract][Full Text] [Related]
27. Clinical validation of a customized multiple signature microarray for breast cancer.
Tan BK; Tan LK; Yu K; Tan PH; Lee M; Sii LH; Wong CY; Ho GH; Yeo AW; Chow PK; Koong HN; Yong WS; Lim DT; Ooi LL; Soo KC; Tan P
Clin Cancer Res; 2008 Jan; 14(2):461-9. PubMed ID: 18223220
[TBL] [Abstract][Full Text] [Related]
28. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
29. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Jönsson G; Staaf J; Olsson E; Heidenblad M; Vallon-Christersson J; Osoegawa K; de Jong P; Oredsson S; Ringnér M; Höglund M; Borg A
Genes Chromosomes Cancer; 2007 Jun; 46(6):543-58. PubMed ID: 17334996
[TBL] [Abstract][Full Text] [Related]
30. A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer.
Xu W; Jia G; Cai N; Huang S; Davie JR; Pitz M; Banerji S; Murphy L
Int J Cancer; 2017 Mar; 140(6):1413-1424. PubMed ID: 27925180
[TBL] [Abstract][Full Text] [Related]
31. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.
Ghosh MG; Thompson DA; Weigel RJ
Cancer Res; 2000 Nov; 60(22):6367-75. PubMed ID: 11103799
[TBL] [Abstract][Full Text] [Related]
32. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
Melchor L; Honrado E; Huang J; Alvarez S; Naylor TL; García MJ; Osorio A; Blesa D; Stratton MR; Weber BL; Cigudosa JC; Rahman N; Nathanson KL; Benítez J
Clin Cancer Res; 2007 Dec; 13(24):7305-13. PubMed ID: 18094411
[TBL] [Abstract][Full Text] [Related]
34. Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Hu X; Stern HM; Ge L; O'Brien C; Haydu L; Honchell CD; Haverty PM; Peters BA; Wu TD; Amler LC; Chant J; Stokoe D; Lackner MR; Cavet G
Mol Cancer Res; 2009 Apr; 7(4):511-22. PubMed ID: 19372580
[TBL] [Abstract][Full Text] [Related]
35. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer.
Stange DE; Radlwimmer B; Schubert F; Traub F; Pich A; Toedt G; Mendrzyk F; Lehmann U; Eils R; Kreipe H; Lichter P
Clin Cancer Res; 2006 Jan; 12(2):345-52. PubMed ID: 16428471
[TBL] [Abstract][Full Text] [Related]
36. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
37. How Young Is Too Young in Breast Cancer?-Young Breast Cancer Is Not a Unique Biological Subtype.
Fu J; Wu L; Fu W; Tan Y; Xu T; Hong Z; Wang F; Li S
Clin Breast Cancer; 2018 Feb; 18(1):e25-e39. PubMed ID: 28802528
[TBL] [Abstract][Full Text] [Related]
38. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers.
Yau C; Benz CC
Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401
[TBL] [Abstract][Full Text] [Related]
39. Genome profiling of ERBB2-amplified breast cancers.
Sircoulomb F; Bekhouche I; Finetti P; Adélaïde J; Ben Hamida A; Bonansea J; Raynaud S; Innocenti C; Charafe-Jauffret E; Tarpin C; Ben Ayed F; Viens P; Jacquemier J; Bertucci F; Birnbaum D; Chaffanet M
BMC Cancer; 2010 Oct; 10():539. PubMed ID: 20932292
[TBL] [Abstract][Full Text] [Related]
40. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
